BridgeBio Pharma Inc (BBIO) — Tangible Net Worth Ratio
BridgeBio Pharma Inc (BBIO) has a Tangible Net Worth Ratio of 100.0% as of December 2020. This metric is calculated by deducting intangible assets ($0.00) from net assets ($107.89 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See working capital position of BridgeBio Pharma Inc to evaluate short-term liquidity relative to the company's equity base.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
BridgeBio Pharma Inc Tangible Net Worth Ratio (2019–2020)
This chart shows how BridgeBio Pharma Inc's Tangible Net Worth Ratio has changed across 2 annual periods from 2019 to 2020. As of December 2020, the ratio stands at 100.0%, reflecting net assets of $107.89 Million with intangible assets of $0.00 USD. See BBIO defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Tangible Net Worth Ratio for BridgeBio Pharma Inc (2019–2020)
The table below presents the year-by-year Tangible Net Worth Ratio for BridgeBio Pharma Inc from 2019 to 2020, covering 2 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see BridgeBio Pharma Inc (BBIO) market capitalisation.
| Year | Tangible NW Ratio | Net Assets (USD) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2020 | 100.0% | $107.89 Million | $0.00 | $703.59 Million | ▲ +0.0 pp |
| 2019 | 100.0% | $475.98 Million | $0.00 | $631.68 Million | — |